New Stock News | Shenzhen Salubris Pharmaceuticals (002294.SZ) Hong Kong IPO prospectus has expired

Shenzhen Salubris Pharmaceuticals Co., Ltd. (abbreviated as Shenzhen Salubris Pharmaceuticals, 002294.SZ) submitted its Hong Kong stock prospectus on February 12, 2026, which will expire six months later, on August 12, 2026. At the time of application, Goldman Sachs, Citigroup, and CITIC SEC served as joint sponsors. According to the previous prospectus, Shenzhen Salubris Pharmaceuticals is a pioneer in the treatment of cardiovascular-kidney-metabolism (cardio-renal metabolic syndrome) diseases in China. Based on data from Frost & Sullivan, in 2024, the company is the second largest pharmaceutical enterprise in China's cardiovascular innovative drug sector by revenue. As of the last practical date (February 4, 2026), according to Frost & Sullivan, the company has the second largest innovative drug pipeline for cardio-renal metabolic syndrome among domestic enterprises, based on scale. The companys product portfolio is strategically centered on innovative drugs while also covering generic drugs, biosimilars, and medical devices, working synergistically to meet the significant unmet medical needs in the field of cardio-renal metabolic syndrome. The company has consistently led the innovative development in the field of cardio-renal metabolic syndrome. As of the last practical date, the company has six innovative drugs: Xinlitai (approved in 2013), Fulitai (approved in 2024), Xinlitin (approved in 2024), Xinchaozhuo (approved in 2025), Fulianan (approved in 2025), and Ennalor (initially approved in 2023, with an expanded indication approved in 2025). The market share of these drugs is rapidly increasing and is expected to become a significant driver of the company's revenue growth. The sales revenue from innovative drugs accounted for 30.1% of total drug sales in 2023, increasing to 37.7% in 2024, and rising from 35.5% in the nine months ending September 30, 2024, to 51.6% in the same period of 2025.